1. Home
  2. ATO vs BIIB Comparison

ATO vs BIIB Comparison

Compare ATO & BIIB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Atmos Energy Corporation

ATO

Atmos Energy Corporation

HOLD

Current Price

$169.21

Market Cap

27.2B

Sector

Utilities

ML Signal

HOLD

Logo Biogen Inc.

BIIB

Biogen Inc.

HOLD

Current Price

$177.23

Market Cap

24.2B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ATO
BIIB
Founded
1906
1978
Country
United States
United States
Employees
N/A
N/A
Industry
Oil/Gas Transmission
Biotechnology: Pharmaceutical Preparations
Sector
Utilities
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
27.2B
24.2B
IPO Year
1987
1991

Fundamental Metrics

Financial Performance
Metric
ATO
BIIB
Price
$169.21
$177.23
Analyst Decision
Hold
Buy
Analyst Count
9
22
Target Price
$169.50
$177.40
AVG Volume (30 Days)
920.0K
2.3M
Earning Date
02-03-2026
02-11-2026
Dividend Yield
2.39%
N/A
EPS Growth
9.22
N/A
EPS
7.46
10.97
Revenue
$4,702,755,000.00
$10,065,900,000.00
Revenue This Year
$13.00
$3.58
Revenue Next Year
$10.35
N/A
P/E Ratio
$22.47
$16.04
Revenue Growth
12.91
4.77
52 Week Low
$136.16
$110.04
52 Week High
$180.65
$185.17

Technical Indicators

Market Signals
Indicator
ATO
BIIB
Relative Strength Index (RSI) 48.26 57.95
Support Level $167.30 $175.00
Resistance Level $169.60 $178.46
Average True Range (ATR) 2.19 3.50
MACD 0.25 -0.44
Stochastic Oscillator 62.64 86.16

Price Performance

Historical Comparison
ATO
BIIB

About ATO Atmos Energy Corporation

Atmos Energy is the largest publicly traded, fully regulated, pure-play natural gas utility in the United States, serving more than 3.3 million customers in Texas, Colorado, Kansas, Kentucky, Louisiana, Mississippi, Tennessee, and Virginia. About two thirds of its earnings come from Texas, where it distributes natural gas in northern Texas and owns an intrastate gas pipeline spanning several key shale gas formations and interconnected with five storage facilities.

About BIIB Biogen Inc.

Biogen is an established biopharmaceutical company focused on treatments for neurological diseases and rare diseases. Its declining multiple sclerosis franchise is its largest revenue generator and contributed 45% of total revenue in 2024. Biogen also generates significant revenue from its CD20 collaboration agreements with Roche (18% of total in 2024), which includes oncology drugs Rituxan and Gazyva and multiple sclerosis drug Ocrevus. Biogen's newer franchises include Spinraza (spinal muscular atrophy, with partner Ionis), Leqembi (Alzheimer's disease, collabroation revenue from its partner Eisai), Skyclarys (Friedreich's ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (amyotrophic lateral sclerosis, Ionis).

Share on Social Networks: